Featured Content

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Long-Term Follow-Up Results of ZUMA-1 Trial

Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.

Subcutaneous Daratumumab Plus CyBorD in Newly-Diagnosed Amyloid Light Chain Amyloidosis

Raymond L. Comenzo, MD, discusses his findings at the ASCO 2018 meeting.

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom's Macroglobulinemia

Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.

More Features>>>

Hematologic Cancers Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs